supplementNot FDA-approvedOTC supplementTA-65 (a proprietary astragaloside IV-derived telomerase activator) is sold in the US as an unregulated dietary supplement, not an FDA-approved drugA separate avian study found no telomere-lengthening effect during post-natal development, illustrating mixed evidence across species and endpoints
TA-65Benefits, Dosage & Interactions
Also known as: Cycloastragenol
TA-65 is a proprietary dietary supplement containing a purified extract from the Astragalus membranaceus plant. The active ingredient in TA-65 is identified as cycloastragenol, a triterpenoid saponin. Research on TA-65 focuses on healthy aging. It is typically taken in the morning.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
Not applicable
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The human metabolic syndrome trial used a proprietary TA-65 astragalus-derived formulation at manufacturer-specified capsule doses in the milligram range[1]
- Route studied
- Oral capsule[1]
- Frequency
- Once daily[1]
- Cycle length
- The human trial followed patients over a period of several months[1]
Reported for TA-65 in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the TA-65 entry is written from. Each number matches an inline marker above.
- [1]TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic SyndromeFernandez ML, Thomas MS, Lemos BS, DiMarco DM, Missimer A, Melough M, Chun OK, Murillo AG, Alyousef HM, Medina-Vera I · Current Pharmaceutical Design · 2018 · Peer-reviewed · PMID 29546832
- [2]TA-65 does not increase telomere length during post-natal development in house sparrow chicks (Passer domesticus)Vangorder-Braid JT, Sirman AE, Kucera AC, Kittilson JD, Kibble TM, Heidinger BJ · Journal of Experimental Zoology Part A: Ecological and Integrative Physiology · 2021 · Peer-reviewed · PMID 33651921
How to track TA-65 doses
Tracking TA-65 well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log TA-65 with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run TA-65 through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review TA-65 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document TA-65 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is TA-65 studied for?
What is TA-65?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
TA-65 is a proprietary dietary supplement containing a purified extract from the *Astragalus membranaceus* plant. The active ingredient in TA-65 is identified as cycloastragenol, a triterpenoid saponin. *Astragalus membranaceus* has a long history of use in traditional Chinese medicine for various conditions, often associated with promoting vitality and supporting immune function. Cycloastragenol itself is derived from astragalosides, which are another group of compounds found in the *Astragalus* root.
The supplement is marketed primarily for its potential role in cellular aging, specifically through its purported impact on telomeres. Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. Telomere shortening is considered a hallmark of cellular aging, and an enzyme called telomerase can help maintain or even extend telomere length. TA-65's mechanism of action is often discussed in relation to telomerase activation.
TA-65 is available as an oral capsule. It is classified as a dietary supplement and is not regulated as a drug by agencies like the U.S. Food and Drug Administration (FDA). Information regarding its efficacy and safety primarily comes from preclinical studies, some human observational studies, and research supported by the supplement's manufacturers or distributors. (Source: PubChem, Examine.com)
What does the research say about TA-65?
Tap a section to expand.
The primary proposed mechanism of action for TA-65, specifically its active compound cycloastragenol, revolves around its claimed ability to activate telomerase. Telomerase is an enzyme composed of a protein and an RNA component. Its function is to synthesize telomeric DNA repeats, thereby maintaining the length of telomeres. Telomeres are repetitive nucleotide sequences at the ends of linear chromosomes that protect genetic information from degradation and fusion during cell replication.
In most somatic cells, telomerase activity is generally low or undetectable, leading to progressive telomere shortening with each cell division. Once telomeres reach a critically short length, cells typically enter a state of replicative senescence, where they stop dividing, or undergo apoptosis (programmed cell death). This process is considered a key contributor to cellular aging.
Cycloastragenol is purported to upregulate the expression or activity of telomerase, potentially leading to increased telomere length or a slower rate of telomere shortening in cells where it is active. This effect has been observed in various *in vitro* (cell culture) and *in vivo* (animal) studies, as well as some human studies. The exact molecular pathway by which cycloastragenol modifies telomerase activity is still under investigation, but it is believed to involve influencing gene expression or post-translational modifications of telomerase components.
While the concept of telomerase activation holds significant interest in longevity research, the clinical implications and the extent of telomere lengthening achievable and its impact on human health span are areas of ongoing scientific inquiry. (Source: PubChem, Examine.com)
Source for this section: Sources for How does TA-65 work?: Jumps to this entry in the sources and references list at the end of the page.
Research on the potential benefits of TA-65 primarily centers on its proposed role in cellular longevity and related physiological functions, stemming from its purported telomerase activation properties. Some human studies, often supported by the supplement's producers, have investigated these areas and yielded observations, though independent replication and larger trial sizes are frequently cited needs for stronger conclusions.
**Potential for Telomere Maintenance:** The core claim for TA-65 is its ability to activate telomerase, which could lead to the maintenance or elongation of telomere length in certain cell populations. Shorter telomeres are associated with increased biological age and various age-related conditions. Studies have suggested that TA-65 use might correlate with modest increases in average telomere length or a reduction in the percentage of short telomeres in some individuals. (Source: Human clinical studies cited by manufacturers, review articles).
**Reported Improvements in Specific Health Markers (Observational):** Some observational human trials have reported associations between TA-65 supplementation and improvements in certain markers, which may or may not be directly linked to telomere effects. These have included:
* **Immune System Support:** Some studies suggest a potential for TA-65 to support immune cell function, which might be related to telomere health in rapidly dividing immune cells. (Source: Human observational studies).
* **Skin Health:** Anecdotal reports and some small studies have suggested potential benefits for skin appearance, possibly linked to cellular rejuvenation processes. (Source: Manufacturer-supported research).
* **Vision and Sexual Function:** Limited data from some trials has indicated self-reported improvements in vision and sexual function in certain populations using TA-65. These findings require much more robust investigation to establish causality. (Source: Human observational studies).
It is important to note that many of the reported benefits are from studies that may have methodological limitations, including small sample sizes, lack of placebo control, or potential conflicts of interest. The scientific community generally calls for more independent, large-scale, randomized controlled trials to conclusively establish the range and magnitude of benefits. (Source: Examine.com, review articles on telomerase activators).
Evidence for TA-65's efficacy is varied, comprising *in vitro* studies, animal models, and a limited number of human trials, some of which are commercially sponsored.
**Preclinical Evidence:**
* **In Vitro Studies:** Laboratory studies using human cells (e.g., fibroblasts, immune cells) have shown that cycloastragenol, the active component of TA-65, can increase telomerase activity and delay cellular senescence. These studies provide foundational mechanistic support for the supplement's claims. (Source: Peer-reviewed scientific literature).
* **Animal Studies:** Research in mice and other animal models has indicated that cycloastragenol can influence telomere length and improve age-related health parameters, such as glucose metabolism and bone density. These studies serve as an intermediate step between cell-based research and human application. (Source: Peer-reviewed scientific literature).
**Human Clinical Evidence:**
* **Observational and Pilot Studies:** Initial human studies, often open-label or small-scale, have reported associations between TA-65 supplementation and changes in telomere length distribution (e.g., a decrease in critically short telomeres) in peripheral blood mononuclear cells over periods ranging from 6 to 12 months. Some studies also noted self-reported improvements in various health parameters as described in the 'benefits' section. (Source: Human clinical studies, often manufacturer-sponsored).
* **Limitations:** A significant limitation in the current body of human evidence is the scarcity of large, independent, randomized, double-blind, placebo-controlled trials. Many existing studies suffer from small sample sizes, lack of appropriate control groups, potential for publication bias, and reliance on self-reported outcomes. Critics often point to these factors when evaluating the strength of the claims made about TA-65. While some studies suggest trends, they are often not robust enough to establish definitive causation or widespread clinical utility. (Source: Examine.com, Cochrane reviews discussing similar longevity interventions).
Overall, while there is some mechanistic and preliminary human data, independent scientific consensus generally awaits more rigorous and larger-scale clinical trials to confirm the broad efficacy and long-term health benefits of TA-65 as a telomerase activator. (Source: NIH ODS, MedlinePlus for general principles of evidence evaluation).
TA-65 is generally considered to be well-tolerated based on available human studies and anecdotal reports, particularly when used within commonly studied ranges. However, as with any supplement, side effects are possible and individual reactions can vary.
Commonly reported side effects, though infrequent and generally mild, have included:
* Mild gastrointestinal upset (e.g., stomach discomfort, nausea) in some individuals.
* Headaches.
* Fatigue, though this can also be reported as an improvement in energy by others.
Given the relatively limited number of large-scale, independent clinical trials, the full spectrum and incidence of potential side effects may not be completely known. Long-term safety data beyond a few years of observation is also limited. Individuals should pay attention to their body's response and report any unusual or persistent symptoms to a healthcare professional.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Use of TA-65 should be approached with caution due to several considerations, particularly its proposed mechanism of action and the current state of scientific evidence.
**Cancer Risk:** The activation of telomerase is a complex biological process. While telomerase maintains telomeres in normal cells, high telomerase activity is also a hallmark of most cancer cells, enabling their uncontrolled proliferation. The theoretical concern exists that exogenous telomerase activation could potentially promote the growth of existing undiagnosed cancers or increase the risk of cancer development. While no direct evidence from human studies firmly links TA-65 to increased cancer risk *in healthy individuals*, this is a significant theoretical concern that requires careful consideration. Individuals with a history of cancer, pre-cancerous conditions, or a strong family history of cancer should exercise extreme caution and consult thoroughly with an oncologist before considering TA-65.
**Immune System Considerations:** *Astragalus* root, from which cycloastragenol is derived, has traditionally been used as an immune modulator. Individuals with autoimmune conditions (e.g., lupus, rheumatoid arthritis, multiple sclerosis) should be particularly cautious, as modulating the immune system could potentially exacerbate their condition. Close medical supervision is advised.
**Lack of Long-Term Safety Data:** The long-term safety of TA-65, especially over many years of continuous use, has not been extensively studied in large human populations. Potential unforeseen effects over prolonged periods remain unknown.
**Pregnancy and Breastfeeding:** There is insufficient reliable information about the safety of TA-65 during pregnancy or breastfeeding. Therefore, it is strongly advised to avoid use during these periods.
**Children:** TA-65 is not intended for use in children, and its safety and efficacy in pediatric populations have not been established.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Contraindications for TA-65 are primarily based on theoretical risks, safety concerns in specific populations, and a lack of sufficient research establishing safety.
* **Pregnancy and Breastfeeding:** Due to insufficient data on safety during these critical periods, TA-65 is contraindicated in pregnant and breastfeeding individuals. The potential effects on fetal development or infants are unknown.
* **Pre-existing Cancers or History of Cancer:** Given the theoretical concerns about telomerase activation and its role in cancer cell proliferation, TA-65 is generally contraindicated in individuals with active cancer, a history of cancer, or a strong predisposition to cancer (e.g., certain genetic mutations). A thorough discussion with an oncologist is imperative before consideration.
* **Autoimmune Diseases:** Individuals with autoimmune conditions (e.g., lupus, rheumatoid arthritis, multiple sclerosis) are cautioned against using TA-65. As the active ingredient is derived from a traditional immune-modulating herb, there is a theoretical risk of exacerbating autoimmune activity. (Source: General considerations for *Astragalus* usage).
* **Organ Transplant Recipients:** Persons who have undergone organ transplants and are taking immunosuppressant medications should avoid TA-65. The immune-modulating properties of *Astragalus* constituents could potentially interfere with immunosuppressive therapy and lead to organ rejection.
* **Children:** TA-65 has not been studied in pediatric populations and is therefore contraindicated for use in children.
* **Known Allergy/Hypersensitivity:** Individuals with a known allergy or hypersensitivity to *Astragalus membranaceus* or any components of TA-65 should avoid its use.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While specific, well-documented drug-drug interactions for TA-65 are limited, its active components derived from *Astragalus membranaceus* may potentially interact with certain medications due to its proposed immune-modulating properties.
* **Immunosuppressants:** Given the traditional use of *Astragalus* as an immune modulator, there is a theoretical concern that TA-65 could interfere with immunosuppressant medications (e.g., azathioprine, cyclosporine, prednisone, tacrolimus) taken by organ transplant recipients or individuals with autoimmune diseases. This could potentially reduce the efficacy of these medications or exacerbate autoimmune conditions.
* **Anticoagulant/Antiplatelet Drugs:** Some studies on *Astragalus* components have suggested potential effects on blood clotting. Though not firmly established for TA-65, individuals taking anticoagulant (blood thinners like warfarin, heparin) or antiplatelet (e.g., aspirin, clopidogrel) medications should exercise caution and discuss with their clinician due to a theoretical increased risk of bleeding.
* **Lithium:** Some herbal constituents can affect kidney function which, in turn, could impact the excretion of lithium, potentially leading to increased lithium levels and associated toxicity. Caution is advised for individuals on lithium therapy.
It is crucial to inform all healthcare providers about all supplements, herbs, and medications being used to avoid potential interactions.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
TA-65 is typically taken orally in capsule form. The typical timing suggested by manufacturers and some studies is in the morning, often on an empty stomach to potentially enhance absorption, though some users may prefer taking it with food to minimize any potential mild gastrointestinal upset. It is generally recommended to follow the specific instructions provided on the product label or by a healthcare professional.
There is no broad consensus on whether taking it with or without food significantly alters its efficacy, as clinical studies often vary in their administration protocols. Some studies have suggested that absorption might be improved in a fasted state, but this is not definitively established for all individuals or formulations.
Consistency in timing, such as taking it at the same time each day, is often emphasized for supplements intended for long-term use to maintain steady systemic levels. Individual needs and tolerance may vary, and adjusting the timing to suit one's digestive comfort is acceptable.
Source for this section: Sources for When should you take TA-65?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with TA-65?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
Frequently asked questions about TA-65
TA-65 is a dietary supplement containing cycloastragenol, derived from the *Astragalus membranaceus* plant. Its proposed mechanism of action is to activate telomerase, an enzyme that helps maintain and potentially lengthen telomeres, which are protective caps on chromosomes that shorten with cell division and are associated with cellular aging. (Source: PubChem, Examine.com)
No, TA-65 is marketed as a dietary supplement and is not approved by the U.S. Food and Drug Administration (FDA) as a drug. Dietary supplements are not subject to the same rigorous pre-market testing and approval process as pharmaceutical drugs. (Source: FDA guidelines for dietary supplements)
While generally reported as well-tolerated, potential mild side effects can include gastrointestinal upset or headaches. Significant warnings include theoretical concerns about telomerase activation in individuals with cancer or a history of cancer, as well as caution for those with autoimmune diseases or individuals on immunosuppressant medications. It is not recommended during pregnancy or breastfeeding. (Source: Examine.com, general supplement safety guidelines)
Effects from TA-65, particularly those related to telomere maintenance, are typically observed over long periods, often several months to a year or more, in studies. This is because cellular processes like telomere lengthening are gradual. Immediate or dramatic effects are not expected. (Source: Manufacturer-supported clinical studies)
Individuals who are pregnant or breastfeeding, children, those with active cancer or a history of cancer, people with autoimmune diseases, and organ transplant recipients on immunosuppressive drugs should generally avoid TA-65. Anyone with a known allergy to *Astragalus* should also avoid it. (Source: Contraindications section, general medical advice)
Interaction risk for TA-65 comes from the rest of the stack: other supplements, prescription medicines, hormone therapy and peptides. Because TA-65 is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers TA-65 with no sign-up.
TA-65 is typically taken in the morning. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for TA-65 plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing TA-65 with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for TA-65 varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of TA-65 depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For TA-65 the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at TA-65?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis(opens PubMed in a new tab)Cell Biol Toxicol · 2025 · PMID 41286474 · https://pubmed.ncbi.nlm.nih.gov/41286474/
- 2.Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction(opens PubMed in a new tab)Geroscience · 2023 · PMID 37086366 · https://pubmed.ncbi.nlm.nih.gov/37086366/
- 3.TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome(opens PubMed in a new tab)Curr Pharm Des · 2018 · PMID 29546832 · https://pubmed.ncbi.nlm.nih.gov/29546832/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 13943286(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/13943286
Verify at
Publisher search links for TA-65. These are places to check the information — they are not citations, so they are not numbered.
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on TA-65?
Plain-text summary, safe to quote verbatim:
TA-65 is a proprietary dietary supplement containing a purified extract from the Astragalus membranaceus plant. The active ingredient in TA-65 is identified as cycloastragenol, a triterpenoid saponin. Research on TA-65 focuses on healthy aging. It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/ta-65
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). TA-65 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ta-65
What compounds are similar to TA-65?
Others in the supplement category or studied for the same goals.
Which goals is TA-65 used for?
Other compounds studied for the same benefits as TA-65.
Continue exploring
See every compound DoseRoutine catalogs for these goals.